, primarily based on the vascular stent concept, have been applied in the clinical practice so far. According to the published studies, urethral stents have justified their clinical application, however with certain limitations. Within an attempt to overcome the limitations, a covered, temporary urethral stent was initially designed by Daniel Yachie and Zeljko Markovic in Allium corporation from Israel. With its triangular shape, the stent is a replica of the obstructive urethral lumen. The follow-up of results was done according to a priori established protocol including the following:UCG, uroflowmetry and interview with patients. Due to stent migration, the stent over stent technique was applied in two case, while reposition by ballooncatheter outward traction was performed in two cases of caudal migration. No irritative discomforts were reported in the first 6 months after stent dwelling. Uroflowmetric controls verified at least four times better results than before the insertion. Given it is the question of covered stent, there is no possibility of proliferative secondary lumen obstruction. On account of soft structure and conic shape of posterior part of stent, no lesions of the external urethral sphincter were manifested. The stent is simply withdrawn after 12 months by outward traction using the forceps at the time when the stent construction turns into soft and straight wire. After 12-16 months in all cases we removel stent and in all patients we find complete rekanalisation without any disuric problem. In 5 cases we find new "contact" stricture on anterior part of stent and treated succeed with balloon recanalisation
INTRODUCTION

U
rethral stricture is the result of scar tissue development after either traumatic or inflammatory injury of the urethra. Although not a life threatening condition, the treatment of urethral stricture is one of the most challenging situations for the urologist and a very troublesome condition for the patient 1, 2 . The treatment of this condition has one main aim -to allow the patient to void with a satisfactory stream and control. This can be achieved by creating a urethra with an adequate caliber either by dilatation or endoscopic incision of the stricture or preferably by one of the many urethroplasty techniques developed for this purpose. Today, when less-invasive treatments fail, the gold-standard for treating a recurrent urethral stricture in a definitive way is to perform an urethroplasty. As described in other chapters of this book, if the stricture is short, urethroplasty is performed by excisi-on and reanastomosis, or in longer strictures by replacing or patching the stenosed segment of the urethra, using tissues taken from other parts of the body such as skin, bladder or buccal mucosa. However, only in experienced hands these procedures are successful in up to 90% of cases because for performing a good and successful urethroplasty, hands capable of neat work, technological perfection and sufficient experience are all necessary. Si-nce the number of urethral strictures is much greater than the number of urologists performing this type of surgery, most urologists still manage their stricture patients with repeated dilatation or urethrotomy, which are less curative methods.
There is a great variation in reporting recurrence rates after urethral dilatations and urethrotomies because of the poor classification of the treated strictures in the reports. Although a 50-60% success rates can be obtained with dilations or urethrotomy in short strictures without spongiofibrosis, in longer strictures and in strictures involving the corpus spongiosum the recurrence rates is about 80% because of new stenotic scar development. Because of repeated dilations or urethrotomy a local inflammatory reac-tion occurs. This inflammation frequently develops to a more extensive stricture than the treated one.
Conventionally, after an endoscopic manipulation and sometimes after a urethral dilation, a urethral catheter is left indwelling for one or for several days to allow urine drainage during the edematous stage of the dilated urethra and to help in its remodeling. At the time the catheter is removed the edema disappears but the tissue-healing process continues to be active. The continuing tissue healing process makes the outcome of the treatment unpredictable which in many cases results in a recurrent stricture.
Although marked progress in restoration of damaged tissues has been achieved over the last decades, the reason for the high rates of urethral stricture recurrence is still not clearly understood.
Wound healing is an integrated series of cellular, physiological and biochemical events occurring in the tissues. There is a difference between wound repair (scarring) and tissue embryogenesis (tissue regeneration). All wounds seems to heal by the same basic process. However there are some basic differences between the healing of an acute and a chronic injury wound, and between a clean vs. an infected wound. During the healing process of a clean wound and under normal conditions there is an equilibrium between collagen synthesis and collagen degradation. Repeated trauma and infection cause a disequilibrium in this process. A change in the equilibrium of the healing process causes an increase in collagen synthesis and a decrease in its degradation, creating a hypertrophic scar tissue development. During the healing process, after the appearance of inflammatory cells, fibroblasts and capillaries invade the fibrin clot to form a contractile granulation tissue. About a week after wounding, the wound clot becomes fully invaded and replaced by activated fibroblasts that are stimulated by growth factors to synthesize and remodel the new collagen-rich matrix 3 . This granulation tissue draws the wound margins together, and the epithelial edges migrate forward to cover the wound surface. This is made easier by the underlying contractile connective tissue, which shrinks to bring the wound margins towards one another. In undisturbed tissue healing, programmed cell death occurs in some of the wound fibroblasts, probably the myofibroblasts, after wound contraction has ceased 4 , marking the stabilization of the scarring process. The healing of an urethra injured during dilation or urethrotomy also develops under similar conditions as with other injured tissues. Although an incised or dilated urethra may appear to be healed within a few weeks, having a complete epithelial coverage, in most cases the stricture will recur because of the ongoing wound healing/scarring process in the deeper layers of the urethra that continues for several months. In urethral stricture this process results in stricture recurrence. As in other cylindrical organs, when happening in the urethra, this scar usually involves the entire circumference of the injured segment causing the recurrence of the circumferential stricture.
Repeated urethral manipulations, such as follow-up cystoscopies for bladder tumors, repeated dilatations, urethrotomy and the insertion of an indwelling catheter after such procedures may cause an inflammation and infection at the urethral wound.
Attempts are being made for stimulating the regeneration of tissues, and some success has been achieved by bridging the lesions with artificial or natural biomaterial "scaffolds" for promoting migration, proliferation and differentiation of cells 5 . Until tissue-regenerative technologies will widely become available, new approaches are being developed for the management of diseases where natural wound repair takes place by scarring. The use of stents in these diseases in general and in recurrent urethral stricture disease in particular, is such a developing novel approach. During the last 15 years the use of stents is being developed as a minimally invasive treatment approach to recurrent urethral strictures. 
Use of Stents in the Treatment of Recurrent Urethral Strictures
As explained above, all wounds heal almost by the same basic process. A chronic wound in the urethra usually fails to heal primarily, as would an acute wound. Healing of a chronic wound is unpredictable. A chronic wound heals up to a point and then the healing process turns toward contraction. Attempts to predict this course and to change the direction of the process with pharmaceutical means, such as local steroid injections failed. However, trials to prevent contraction of the wound by mechanical interference showed very encouraging results, especially in urethral strictures. The idea behind the use of stents for preventing urethral stricture recurrence is based on such mechanical interference to prevent the scarring process ending in contraction. The introduction of large caliber metal stents for use in the urinary tract opened up the possibility of this new approach for the treatment of urethral strictures.
Since the introduction of stents in the late 1980's for the treatment of urethral strictures, two different concepts have been studied in order to prevent the scarring process ending in contraction. For this purpose different stents were either permanently implanted, or temporarily left indwelling for certain periods of time and then removed. Each of these concepts were based on different modes of mechanical interference provided by the permanent and temporary stents.
Permanent Stents
The era of self-expanding stents in medicine started with the introduction of the braided Wallstent developed by Hans Wallsten for vascular use. (Figure 1a-d) This stent became the most widely recognized one used in many medical disciplines, including urology. The design of this stent was based on a wire braiding technology called the "Chinese finger trap", an old Chinese trick in which one can insert a finger which is trapped when the finger is retracted. This braiding technology is also used widely for manufacturing of coaxial cables. The concept of using a permanently implanted stent to maintain the patency of a strictured bulbar urethra was first described by, Milroy and associates in 1988. This use was a natural extension of the concept of vascular stenting, where the stent becomes imbedded into the wall of the blood vessel, covered by endothelium and keep it open. Vascular stents are about 1.2 times the blood vessel diameter to ensure its anchoring, without causing unnecessary pressure to the wall of the vessel. After its release, the entire mesh stent becomes in contact with the vessel wall. The constant pressure the stent struts applies to the wall causes a traumatic damage to the endothelium. This damage induces a chain tissue reaction until the stent becomes covered with endothelium. In the urethra also these permanent stents were planned to push themselves into the walls of the urethra and remain permanently in the wall to act as reinforcement, like the iron bars in concrete pipes, for keeping the lumen open. Milroy and al. described the use of the UroLume Wallstent (American Medical Systems, Minnetonka, MN, USA) stent after dilating the urethra.
The Urolume Wallstent is made from a biocompatible non-magnetic superalloy woven into a tubular mesh which is flexible and self-expanding to 42F. Soon after the Urolume Wallstent another mesh stent (knitted) became available: the thermo-expandable Memotherm (C. R. Bard -USA). Both stents were deployed under vision using an endoscopic tool on which the stent comes loaded. ( Figure  2 ) The large caliber and the radial expansion force of the stents kept these stents in place until the stent pushes itself into the urethral wall and epithelialization completely buries it.
Clinical Experience with the Urolume Wallstent
Candidates for UroLume Wallstent or Memotherm stent placement were patients having a bulbar urethral stricture less than 3 cm long and at least 10 mm of healthy urethra distal to the external sphincter. The stent to be implanted was chosen to be at least 10 mm longer than the stricture, because 5 mm has to be added to each end of the estimated stricture length. The North American UroLume Trial (between March 1989 and April 1996) enrolled 179 patients with recurrent strictures in the bulbar urethra. Most of them had been treated for more than 5 years by dilatations or urethrotomies at least 5 times. The initial results of this study were very encouraging. Insertion of the UroLume stent decreased retreatment rates from 75.3% before insertion to 14.3% after insertion in the 105 patients fo-
Endourethral prostheses for urethral stricturellowed for at least 1 year 7 . No similar study with large number of patients was done with the Memotherm.
During the 2-year follow-up, narrowing of the stent lumen was noted in 74 of 179 patients (41.3%) at one or more follow-up visits. This narrowing was the result of urethral epithelium overgrowth through the interstices of the stent. In sixty-two (83%) of these cases the narrowing was mild, whereas in 12 patients (16%) there was a need for transurethral resection of the occluding tissues 7 . However, there were centers which reported 87% success rates with 4.3 years followup.
The incidence of hyperplastic tissue ingrowth more frequently occurred in post-traumatic strictures. The use of permanent stents was found to be contraindicated in traumatic strictures because of the excessive intra-stent tissue proliferation causing very high rates of intra-stent restenosis.
Because of their shape and large caliber, the use of Urolume Wallstent or other permanent stents were limited to the bulbar urethra. Their use in the mobile parts of the urethra was found to be risky, because of the sharp ends of these stents causing pain and the possibility of causing an injury or even perforate the urethra. The permanent stents also had an important limitation in patients who underwent urethroplasty using skin and subsequently developed a new stricture: these stents could not cut through the skin patch used and could not become entirely incorporated. A part of the stent at the place of the skin patch remained bare in the lumen of the urethra and a part of it became covered by urethral epithelium. In such cases, surgery is necessary to remove the partly imbedded stent. Otherwise the bare wires of the stent could become the core for stone formation.
Despite the initial optimistic results obtained with the permanent stents the enthusiasm in using them started to wane with time. Reports started to appear on the high restenosis rates developing even after 3-6 years. These reports also noted the difficulties in their removal which frequently involved resection of the entire urethral segment together with the stent and performing a formal replacement urethroplasty [11] [12] [13] [14] [15] In some patients who developed an intrastent occlusion a temporary stent was inserted instead of surgical removal of the permanent stent and performing a urethroplasty.
The accumulating experience narrowed the indications for using the self expanding permanent stents to frail patients or to those refusing surgical treatment 14 . The Urolume Wallstent was the only stent applying for and receiving an FDA approval for the treatment of urethral strictures. However, because of the reports on high intra-stent restenosis rates, nowadays both the Urolume Wallstent and the Memotherm are rarely used.
Temporary Stents
In 1989, another concept was developed for the treatment of recurrent urethral strictures. This concept was based on a large-caliber temporary urethral stent to be introduced in reduced profile and deployed to self-expand. The concept of using a temporary device instead of a permanent one was based on an entirely different mechanical interference technique than the one expected from the permanent stents. The new concept involved placement of an intralumenal stent in the stenotic urethra after dilating or incising it, and leaving the stent in place long enough to act as a mould until stabilization of the scarring process and then to be removed. The presence of the stent in the . The temporary large caliber UroCoil System stents were made of a nickel-titanium alloy (Nitinol) had an expanded calibre of 24-30 F with an insertion caliber of 17 F. They came in three different configurations, allowing their use along the entire urethra, from the bladder neck to the external meatus 17, 18 . Later the Memokath urethral stent (Engineers & Doctors. Danemark) which was also made of nitinol was launched in Europe
19
.
The introduction of these stents opened a new minimally invasive approach in the treatment of recurrent urethral stricture disease 20 . In addition to their use in urethral strictures they were also used successfully in the treatment of urethro-vesical anastomotic stenoses 21, 22 . (Figure 3 a- 
Differing from the permanent stents, the experience with the temporary stents showed that using them in posttraumatic strictures or in post urethroplasty strictures where skin was used is not a contraindication because they did not become infiltrated by tissue and they did not have to cut through the skin patch to become imbedded. However, some of the patients in whom a UroCoil or a Memokath stent was inserted developed a reactive hypertrophic tissue partly of completely occluding the ends of the stents.
Clinical experience and results with the UroCoil System
From 1990 to 2000, 172 patients with recurrent urethral strictures have been treated with the three configurations of the UroCoil-System stents by the author (Figure 4 a-b) . The strictures were situated all along the urethra, from the urethral meatus up to the posterior urethra 23 . All patients had undergone at least three urethral dilatations or two optical urethrotomies during the year preceding the procedure. Patients with acute urethral infections received intensive antibiotic treatment before the procedure. The average indwelling time of the stent was 12 (range 9-14) months and average follow-up after stent removal is 36 (range 8-50) months. At the end of the second year, 83% of the patients had a patent urethra and were voiding with a stream that was found to be within the normal range. The recurrence rate rose to 20% in year 3 but stayed at the same level during year 4 . Although the UroCoil System stents were developed by a US based company it did not apply for an FDA approval. These stents were used worldwide but not in the US. They disappeared from the market after the company which developed the technology was acquired by a major medical device company which was interested more in the other applications of the technology and not in the urology market. At this stage there are no stents for use in the urethral strictures in USA. However a multicentric study is being done in the US with the Memokath urethral stent. Endourethral prostheses for urethral stricture
Limitations of Previous Generation permanent and Temporary Stents
Accumulating experience showed that adopting and then adapting permanent stents developed for the vascular tree to the prostatic and bulbar urethra showed that they did not always fulfill our needs. Also the previous generation temporary urethral stents (UroCoil System, Memokath 044, Memokath 045) had their limitations.
One of the problems with the self-expanding metallic permanent and temporary stents is their shortening on release. The deployed Urolume Wallstent is about 30% shorter than its constricted length. The UroCoils shorten by ∼ 40-50% upon deployment and the Memokath by ∼ 10%. In less experienced hands this shortening may cause deployment inaccuracies.
Common problems seen with both the permanent and temporary stent were: -development of sphincteric dysfunction when they were deployed in the near vicinity of the external sphincter -tissue proliferation into the stent lumen (mainly seen with the permanent stents, occasionally between the loops of the temporary stents)
-tissue proliferation at the ends of the stents The external sphincter, during its contraction, gives a fusiform shape to the urethral lumen. This phenomenon is a standard finding seen during ascending urethrographies. Placing a cylindrical stent with a ring shaped sphincteric end adjacent to a sphincter often interferes with the proper functioning of the sphincter causing in 10-20% of the patients a partial or total incontinence 24 , especially when one end of the stent has to be positioned near the external sphincter.
Additional problems encountered with the current urethral stents were occasional tissue ingrowth between the loops of the coils or reactive tissue proliferation at their sphincteric end, causing partial or complete obliteration of the stent. The reason of this reactive tissue proliferation is the radial stiffness of the sphincteric end of the stent causing repeated friction to the urethral wall during opening and closure of the sphincter. (A similar phenomenon occurs in vascular stents, where reactive tissue may develop at both ends of the stent. This is named the "candy-wrap effect" by the cardiologists and interventional radiologists.)
These limitations induced a search for new designs based on the specific needs of the site, the urethra. The idea to design a new bulbar urethral stent was born after analyzing the deficiencies of the current urethral stents and making conceptual changes in the design.
Characteristics of the New Allium Bulbar Urethral Stent
The bulbar urethra is the widest part of the entire urethra immediately below the external sphincter, in a place frequently compressed when sitting. As such, the stent for this area had to fit the dimensions and the shape of an adult bulbar urethra to act as a mould, without interfering to the function of the sphincter, preventing tissue ingrowth into the lumen and tissue proliferation at its ends. It had to be inserted in reduced caliber, non-shortening at deployment and shape recoil ability to make it effective and comfortable to the patient. The Allium Bulbar Stent was engineered taking into consideration all these requirements. It has a nitinol wire skeleton which is covered with a biocompatible polymer resistant to the environment of urine and make it an impermeable walled tube to prevent tissue ingrowth into the lumen. This structure expands to 45F after deployment. It is deployed using its special 24 F delivery mechanism for easy endoscopic insertion. Since the stent does not shorten during deployment its position-FIGURE 5A URETROCYSTOGRAPHY: ANULAR SUBTOTAL STRICTURE OF BULBAR URETHRA
FIGURE 5B URETROCYSTOGRAPHY:STATUS POST INSER-TION OF ALLIUM COVER STENT
ing is very accurate. After its release the stent continues to self-expand with gentle but continuous radial expansion pressure until it reaches its maximal expansion. Sometimes it may take a few days to reach its full expansion.
Its low radial force end segments reduce mechanical interference to the sphincteric function and also reduce the friction between the end of the stent and the urethral wall. Having a "sphincter friendly" segment of low radial force in a lumen adjacent to a sphincter allows the stent to be more accurately positioned in the lumen with its sphincteric end even touching the sphincter. This segment fits itself dynamically to the diameter and shape changes of the sphincter. It dynamically fluctuates with the diameter of the lumen so as to remain in contact with the lumen wall at all times. When the sphincter closes and the diameter of the lumen adjacent to the sphincter decreases, the diameter of the end segment of the stent also decreases in a conical shape while remaining in contact with the lumen wall. When the sphincter opens for voiding, and the diameter of lumen adjacent to the sphincter increases, the diameter of the end segment also increases, always remaining in contact with the lumen wall allowing unobstructed urination.
Its downstream end segment also has a low radial force to eliminate the sharp pressure gradient that otherwise exists along the lumen wall, reducing the friction and the resulting reactive tissue growth.
The caliber of the stent is larger than the post-bulbar urethra to prevent its downstream migration. Its large caliber allows passage of endoscopic instruments up to 19F to the bladder.
After its deployment when sitting on a hard surface the stent can becomes compressed making the presence of the stent comfortable to the patient. After being compressed during sitting the stent returns to its original shape and caliber when the compressing force disappears.
Insertion Technique
A prophylactic antibiotic, such as a cephalosporin is administered, starting 1 day before the procedure and continuing for at least 5 days. In cases where the urine culture shows an infection, the antibiotic is chosen according to the sensitivity.
The entire insertion procedure is done under vision, however fluoroscopic insertion also is possible. Before insertion of the stent either an internal urethrotomy, or a balloon dilatation or a progressive dilatation of the stricture is done. This dilation should allow insertion of the 24F delivery device easily.
For inserting the appropriate length stent two measurements are taken:
1 -the distance between the downstream end of the external sphincter and the proximal (upstream) end of the stricture 2 -the length of the strictured segment After dilation of the stricture a Foley-like ruler catheter having marks each centimeter is inserted into the bladder. After inflating the balloon the catheter is pulled gently until the balloon contacts the bladder neck. Then a small caliber cystoscope with a 30° lens is advanced aside the ruler catheter until the downstream end of the external sphincter is seen. The marks on the catheter are counted pulling the cystoscope outward until the upstream end of the stricture is seen. This gives the distance between the external sphincter and the stricture. The cystoscope is continued to be pulled outward until the downstream end of stricture is reached to measure the length of the stricture. The two measurements are added to each other to calculate the distance between the external sphincter and the downstream end of the stricture. To choose the stent with the appropriate length one centimeter is added to this length because the downstream end of the stent should cross into the healthy part of the urethra to make sure that the entire stricture is covered. Endourethral prostheses for urethral strictureAfter deciding the appropriate stent length a standard 30° optic element of a cystoscope is inserted into the delivery tool. Under vision the downstream end of the external sphincter is reached. Keeping this position the trigger is pulled to gradually retract the overtube covering the stent to allow expansion of the stent. During the entire procedure the sphincter should be seen but not entered. After complete release of the stent the delivery tool is gently pulled out using gentle circular movements. Immediately after stent release, a pressure can be seen at the site of the stricture. The continuing radial pressure of the stent opens the stricture to the maximum caliber of the stent. Once the release is started the stent cannot be retracted into the delivery device. However until 50% of the stent is released it can be repositioned by manipulating the delivery tool. If the entire stent is malpositioned, it should be removed and a new one inserted.
Follow-up
During the indwelling period of the stent (12 months or more) it is advisable to acidify the urine (pH below 6) and maintain a urine output of 1500-2000 ml/day to delay biofilm formation and encrustations. Monthly urine cultures and appropriate antibiotics are prescribed, especially to patients who had a chronic infection before stenting ( Figure 5 a-d, Figure 6 a-b, Figure 7 a-b) .
Removal of the Allium Bulbar Stent
Because of their complete polymeric cover, these stents do not allow tissue ingrowth into their lumen. Removal of the stent is, therefore very easy, even after a year or more. The urethra is filled with 10-20 ml 2% lignocaine gel, which is left in place for 10 minutes. Then the stent is removed by holding the last loop of the coil with an endoscopic grasping forceps, and is pulled out gently until the entire stent emerges. If the pulling force during removal exceeds 500-600 grams the stent starts to unravel. This is a safety feature to prevent trauma to the distal urethra during removal.
One or two days after removal of the stent, the first uroflow measurement is made to mark the post-removal Qmax baseline; this is repeated 1, 3, 6, 12 and 24 months after removal. A decrease of 15% in Qmax from the baseline can be accepted as normal, but a decrease of more than 20% on two consecutive measurements is regarded suspicious as the first symptom of stricture recurrence. In such a case a urethrogram is performed to establish the cause of the decrease in flow.
Urine culture is performed immediately after stent removal and, where positive, it is repeated until the urine becomes sterile after appropriate treatment.
Clinical Experience with the Allium Bulbar Urethral Stent
Since 2003 this new stent has been used in 24 patients who had frequently recurring bulbar urethral strictures, 8 of them 1 cm. below the sphincter. Before stent insertion the strictures were dilated either with a high pressure dilating balloon to 30F (18 pts.) or by urethrotomy (6 pts.). The stents were inserted either endoscopically (19 pts.) or under fluoroscopy (5 pts.). All the insertion procedures were done under ambulatory conditions and under topical anesthesia of the urethra. In 11 patients the stricture was of traumatic origin and in 13 inflammatory (after indwelling catheterization or TURP). The age of patients were 34 -72. The stents were left indwelling for 8 to 14 months (av. 11 months). Follow-up after stent removal was 20 -24 months. Only in 2 patients a recurrence was seen after 12 and 18 months. No stent migration was observed. No patient requested stent removal because of discomfort. Pa- Recently an additional group of patients who developed anastomotic strictures after radical prostatectomy or cysto-prostatectomy are being treated with a slightly different design of this new large caliber stent.
CONCLUSIONS
Management of recurrent urethral strictures with a temporarily inserted stent is a simple and satisfactory procedure which can be performed by every urologist. The learning curve is very short. Whatever the reason, if a decision is taken to remove the stent, it can be removed in a few minutes even in an office under topical anesthesia at any time. The ease in the removability of the temporary stents makes this procedure a reversible one.
The high success rates obtained after failure of repeated dilations and urethrotomies with the previous generation of temporary stents and the new Allium Bulbar Urethral Stent, indicate that the use of temporary stents can replace repeated urethral manipulations for maintenance of an adequate urethral caliber. The smoothness and softness of these stents allow their use even in young patients, without interfering with their sexual life. The results obtained in recurrent post-traumatic urethral strictures are also very promising. As the stents remain in the urethral lumen without becoming epithelialized, they can be used also in patients who underwent urethroplasty using skin. Largecalibre temporary urethral stents enable most bulbar urethral strictures to be treated in a minimally invasive way. These results indicate that more extensive use of temporary stents in the treatment of recurrent urethral strictures will reduce the number of repeated dilatations or urethrotomies which are non-curative procedures. Since the results obtained using the long-term, large caliber temporary stents approach the results obtained with urethroplasty their use is advised before deciding to perform an urethroplasty. In many cases this approach may become the primary treatment of urethral strictures, superseding urethroplasty.
SUMMARY
Uretralni stentovi postoje u urolo{koj i interventno uroradiolo{koj klini~koj praksi oko 20 godina. U odnosu na etiologiju uroopstrukcije naj~e{} se radi o posttraumatskim strikturama bulbarne uretre. Za to vreme konstruisani su brojni modeli, razli~itog materijala, dizajna i na~ina insercije. Metalni uretralni stentovi se primenjuju u slu~ajevima ireverzibilne opstruktivne lezije naj~e{}e na nivou bulbarne uretre. Mogu biti trajni i privremeni a u odnosu na na~in insercije samo{ire}i, balonekspandibilni ili termoekspandibilni. Naj~e{}i materijal od koga su stentovi izradjeni je legura nitino. U odnosu na algoritam primene ove metode, terapijski stavovi su zna~ajno izmenjeni od 2003. godine kada je primenjen privremeni prekriveni metalni stent Allium. Prva klini~ka primena radjena je u Klini~kom centru Srbije. Prikazani su trogodi{nji rezultati na osnovu kojih, kao i na osnovu rezultata u primeni generacijski starijih modela, se mo'e zaklju~iti da su uretralni stentovi Allium stent metod izbora za ireverzibilnu urostazu na nivou uretre.
Klju~ne re~i: stent, striktura uretre
